T-cell Prolymphocytic Leukemia.
Loading...
Embargo End Date
ICR Authors
Authors
Sud, A
Dearden, C
Dearden, C
Document Type
Journal Article
Date
2017-04-01
Date Accepted
2016-08-12
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, cytogenetics, and molecular features. The current therapeutic approach relies on immunotherapy followed by a hematopoietic stem cell transplant in selected cases. Clinical outcomes are generally poor, although insights from genomic and molecular studies may increase our understanding of this disease, with the promise of additional effective therapeutic options.
Citation
Hematology/oncology clinics of North America, 2017, 31 (2), pp. 273 - 283
Source Title
Publisher
W B SAUNDERS CO-ELSEVIER INC
ISSN
0889-8588
eISSN
1558-1977